CULVER CITY, Calif.--(BUSINESS WIRE)--Jul. 31, 2015--
NantKwest, Inc. (formerly Conkwest, Inc.) (Nasdaq: NK), a clinical-stage
immunotherapy company focused on harnessing the power of the innate
immune system by using the natural killer cell to treat cancer,
infectious diseases and inflammatory diseases, announced today the
closing of its initial public offering of 9,531,200 shares of common
stock at a price to the public of $25.00 per share, which included
1,243,200 shares sold pursuant to the exercise in full by the
underwriters of the offering of their option to purchase additional
shares. NantKwest estimates the net proceeds from the offering were
approximately $222.5 million after deducting the underwriting discounts
and commissions and other offering expenses. Concurrently with the
initial public offering, NantKwest also sold 680,000 shares of its
common stock in a separate private placement to Celgene Corporation, an
existing stockholder, at the initial public offering price, for
additional proceeds of $17.0 million.
BofA Merrill Lynch, Citigroup Global Markets Inc., Jefferies LLC and
Piper Jaffray acted as joint book-running managers for the offering, and
MLV & Co. LLC acted as co-manager.
A copy of the final prospectus related to the offering may be obtained
from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention:
Prospectus Department, or by email at dg.prospectus_requests@baml.com;
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by email at prospectus@citi.com,
or by telephone at (800) 831-9146; Jefferies LLC, Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, or by telephone at (877) 547-6340, or by email at Prospectus_Department@Jefferies.com;
or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet
Mall, Suite 800, Minneapolis, MN 55402, or by email at prospectus@pjc.com,
or by telephone at (800) 747-3924.
Registration statements relating to these securities have been filed
with the Securities and Exchange Commission and became effective on July
27, 2015. Copies of the registration statements, as amended, can be
accessed through the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150731005720/en/
Source: NantKwest, Inc.
NantKwest
Jen Hodson
562-397-3639
